peoplePerson
Robert A. Fenstermaker
Robert Fenstermaker invented SurVaxM, a survivin-targeted vaccine in late-stage trials for glioblastoma.
Neurosurgeon-scientist whose survivin peptide mimic vaccine SurVaxM showed encouraging survival in phase 2 and advanced to a randomised trial in newly diagnosed glioblastoma.
Role
Chair, Department of Neurosurgery; Director, Neuro-Oncology Program
Institution
Specialisms
GlioblastomaCancer vaccinesSurvivin
Profiles
| Title | Journal | Year |
|---|---|---|
| Phase 2 trial of SurVaxM with temozolomide in newly diagnosed glioblastoma | Journal of Clinical Oncology | 2023 |
Pages like this
not linked directly; found by shared links- ProductDCVax-L
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
- ProductRindopepimut
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
- InstitutionThe Wistar Institute
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
- InstitutionComprehensive Cancer Center Tübingen-Stuttgart
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
- RoadmapImmunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.